

Adrian S Ray

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4075291/publications.pdf>

Version: 2024-02-01

102
papers

11,018
citations

44069

48
h-index

31849

101
g-index

105
all docs

105
docs citations

105
times ranked

12634
citing authors

#	ARTICLE	IF	CITATIONS
1	Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	1,279
2	Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. <i>Nature</i> , 2016, 531, 381-385.	27.8	1,245
3	Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. <i>MBio</i> , 2018, 9, .	4.1	1,142
4	Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1- <i>f</i>][triazin-4-amino] Adenine <i>N</i> -Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1648-1661.	6.4	547
5	GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. <i>Scientific Reports</i> , 2017, 7, 43395.	3.3	373
6	Toxicity of Antiviral Nucleoside Analogs and the Human Mitochondrial DNA Polymerase. <i>Journal of Biological Chemistry</i> , 2001, 276, 40847-40857.	3.4	362
7	Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. <i>Antiviral Research</i> , 2010, 85, 39-58.	4.1	314
8	Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus. <i>Antiviral Research</i> , 2016, 125, 63-70.	4.1	302
9	Mechanism of Active Renal Tubular Efflux of Tenofovir. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3297-3304.	3.2	298
10	Structural basis for RNA replication by the hepatitis C virus polymerase. <i>Science</i> , 2015, 347, 771-775.	12.6	294
11	GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2018, 155, 1463-1473.e6.	1.3	238
12	Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 2471-2477.	3.2	221
13	Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat. <i>Kidney International</i> , 2014, 86, 350-357.	5.2	198
14	Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 890-899.	4.7	185
15	Synthesis and antiviral activity of a series of 1- <i>H</i> -substituted 4-aza-7,9-dideazaadenosine C-nucleosides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 2705-2707.	2.2	173
16	Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1983-1991.e3.	4.4	153
17	Implications of Efficient Hepatic Delivery by Tenofovir Alafenamide (GS-7340) for Hepatitis B Virus Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3563-3569.	3.2	133
18	Role of Purine Nucleoside Phosphorylase in Interactions between 2,3-Dideoxyinosine and Allopurinol, Ganciclovir, or Tenofovir. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 1089-1095.	3.2	132

#	ARTICLE	IF	CITATIONS
19	Cobicistat Boosts the Intestinal Absorption of Transport Substrates, Including HIV Protease Inhibitors and GS-7340, <i>In Vitro</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5409-5413.	3.2	126
20	Sensitivity of Mitochondrial Transcription and Resistance of RNA Polymerase II Dependent Nuclear Transcription to Antiviral Ribonucleosides. <i>PLoS Pathogens</i> , 2012, 8, e1003030.	4.7	119
21	Effects of Human Immunodeficiency Virus Protease Inhibitors on the Intestinal Absorption of Tenofovir Disoproxil Fumarate <i>In Vitro</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3498-3504.	3.2	118
22	Chronic Administration of Tenofovir to Rhesus Macaques from Infancy through Adulthood and Pregnancy: Summary of Pharmacokinetics and Biological and Virological Effects. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3144-3160.	3.2	114
23	Discovery of the First <i>C</i> -Nucleoside HCV Polymerase Inhibitor (GS-6620) with Demonstrated Antiviral Response in HCV Infected Patients. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1812-1825.	6.4	108
24	Synthesis and Significant Cytostatic Activity of 7-Hetaryl-7-deazaadenosines. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 5498-5507.	6.4	101
25	Transporter Expression in Liver Tissue from Subjects with Alcoholic or Hepatitis C Cirrhosis Quantified by Targeted Quantitative Proteomics. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1752-1758.	3.3	100
26	Design and Profiling of GS-9148, a Novel Nucleotide Analog Active against Nucleoside-Resistant Variants of Human Immunodeficiency Virus Type 1, and Its Orally Bioavailable Phosphonoamidate Prodrug, GS-9131. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 655-665.	3.2	93
27	Mechanism for Effective Lymphoid Cell and Tissue Loading Following Oral Administration of Nucleotide Prodrug GS-7340. <i>Molecular Pharmaceutics</i> , 2013, 10, 459-466.	4.6	93
28	Metformin Is a Substrate and Inhibitor of the Human Thiamine Transporter, THTR-2 (SLC19A3). <i>Molecular Pharmaceutics</i> , 2015, 12, 4301-4310.	4.6	79
29	Molecular Assessment of the Potential for Renal Drug Interactions between Tenofovir and HIV Protease Inhibitors. <i>Antiviral Therapy</i> , 2007, 12, 267-272.	1.0	76
30	Probing the Molecular Mechanisms of AZT Drug Resistance Mediated by HIV-1 Reverse Transcriptase Using a Transient Kinetic Analysis. <i>Biochemistry</i> , 2003, 42, 8831-8841.	2.5	75
31	GS-9219: A Novel Acyclic Nucleotide Analogue with Potent Antineoplastic Activity in Dogs with Spontaneous Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2008, 14, 2824-2832.	7.0	74
32	6-(Het)aryl-7-Deazapurine Ribonucleosides as Novel Potent Cytostatic Agents. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 460-470.	6.4	73
33	A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT. <i>Aids</i> , 2005, 19, 1751-1760.	2.2	70
34	Natural Substrate Concentrations Can Modulate the Prophylactic Efficacy of Nucleotide HIV Reverse Transcriptase Inhibitors. <i>Journal of Virology</i> , 2011, 85, 6610-6617.	3.4	69
35	The K65R Reverse Transcriptase Mutation in HIV-1 Reverses the Excision Phenotype of Zidovudine Resistance Mutations. <i>Antiviral Therapy</i> , 2006, 11, 155-163.	1.0	69
36	Role of Mitochondrial RNA Polymerase in the Toxicity of Nucleotide Inhibitors of Hepatitis C Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 806-817.	3.2	68

#	ARTICLE	IF	CITATIONS
37	Evaluation of the Endothelin Receptor Antagonists Ambrisentan, Bosentan, Macitentan, and Sitaxsentan as Hepatobiliary Transporter Inhibitors and Substrates in Sandwich-Cultured Human Hepatocytes. <i>PLoS ONE</i> , 2014, 9, e87548.	2.5	63
38	<i>In Vitro</i> Evaluation of the Anti-HIV Activity and Metabolic Interactions of Tenofovir and Emtricitabine. <i>Antiviral Therapy</i> , 2006, 11, 377-384.	1.0	60
39	Synthesis and anti-HIV activity of GS-9148 (2'-Fd4AP), a novel nucleoside phosphonate HIV reverse transcriptase inhibitor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 1120-1123.	2.2	58
40	Intracellular Metabolism of the Nucleotide Prodrug GS-9131, a Potent Anti-Human Immunodeficiency Virus Agent. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 648-654.	3.2	58
41	Assessment of GS-9219 in a Pet Dog Model of Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2009, 15, 3503-3510.	7.0	58
42	Design, synthesis, and anti-HIV activity of 4'-modified carbocyclic nucleoside phosphonate reverse transcriptase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 1739-1746.	3.0	58
43	Discovery of GS-9131: Design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 3606-3617.	3.0	57
44	Mechanistic Studies to Understand the Progressive Development of Resistance in Human Immunodeficiency Virus Type 1 Reverse Transcriptase to Abacavir. <i>Journal of Biological Chemistry</i> , 2002, 277, 40479-40490.	3.4	56
45	Simultaneous quantitation of the nucleotide analog adefovir, its phosphorylated anabolites and 2'-deoxyadenosine triphosphate by ion-pairing LC/MS/MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 848, 335-343.	2.3	54
46	Renal drug-drug interactions: what we have learned and where we are going. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 433-448.	3.3	54
47	Novel Nucleotide Human Immunodeficiency Virus Reverse Transcriptase Inhibitor GS-9148 with a Low Nephrotoxic Potential: Characterization of Renal Transport and Accumulation. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 150-156.	3.2	52
48	Nucleotide Analogue Prodrug Tenofovir Disoproxil Enhances Lymphoid Cell Loading following Oral Administration in Monkeys. <i>Molecular Pharmaceutics</i> , 2009, 6, 1145-1151.	4.6	52
49	Visualizing the Molecular Interactions of a Nucleotide Analog, GS-9148, with HIV-1 Reverse Transcriptase-DNA Complex. <i>Journal of Molecular Biology</i> , 2010, 397, 967-978.	4.2	48
50	Transporter Expression in Noncancerous and Cancerous Liver Tissue from Donors with Hepatocellular Carcinoma and Chronic Hepatitis C Infection Quantified by LC-MS/MS Proteomics. <i>Drug Metabolism and Disposition</i> , 2018, 46, 189-196.	3.3	43
51	Insights into the Molecular Mechanism of Inhibition and Drug Resistance for HIV-1 RT with Carbovir Triphosphate. <i>Biochemistry</i> , 2002, 41, 5150-5162.	2.5	42
52	Evaluation of the Effect of Cobicistat on the <i>In Vitro</i> Renal Transport and Cytotoxicity Potential of Tenofovir. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4982-4989.	3.2	41
53	Metabolism and Pharmacokinetics of the Anti-Hepatitis C Virus Nucleotide Prodrug GS-6620. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1943-1951.	3.2	40
54	Application of kinase bypass strategies to nucleoside antivirals. <i>Antiviral Research</i> , 2011, 92, 277-291.	4.1	39

#	ARTICLE	IF	CITATIONS
55	Inhibition of Hepatitis C Virus Replication by GS-6620, a Potent <i>C</i> -Nucleoside Monophosphate Prodrug. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1930-1942.	3.2	38
56	GS-9191 Is a Novel Topical Prodrug of the Nucleotide Analog 9-(2-Phosphonylmethoxyethyl)Guanine with Antiproliferative Activity and Possible Utility in the Treatment of Human Papillomavirus Lesions. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2777-2784.	3.2	37
57	Synthesis and characterization of 2- ² -C-Me branched C-nucleosides as HCV polymerase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 4127-4132.	2.2	37
58	Novel Use of a Guanosine Prodrug Approach To Convert 2',3'-Didehydro-2',3'-Dideoxyguanosine into a Viable Antiviral Agent. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 887-891.	3.2	36
59	Effective metabolism and long intracellular half life of the anti-Hepatitis B agent adefovir in hepatic cells. <i>Biochemical Pharmacology</i> , 2004, 68, 1825-1831.	4.4	36
60	Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. <i>Antiviral Therapy</i> , 2007, 12, 267-72.	1.0	33
61	Pharmacokinetics of cobicistat boosted elvitegravir administered in combination with rosuvastatin. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 649-656.	2.0	32
62	Synthesis, anti-HIV activity, and resistance profiles of ribose modified nucleoside phosphonates. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 6785-6789.	2.2	31
63	Intracellular interactions between nucleos(t)ide inhibitors of HIV reverse transcriptase. <i>AIDS Reviews</i> , 2005, 7, 113-25.	1.0	31
64	Interaction of 2,4-Diaminopyrimidine-Containing Drugs Including Fedratinib and Trimethoprim with Thiamine Transporters. <i>Drug Metabolism and Disposition</i> , 2017, 45, 76-85.	3.3	30
65	Lack of a Metabolic and Antiviral Drug Interaction between Tenofovir, Abacavir and Lamivudine. <i>Antiviral Therapy</i> , 2005, 10, 451-457.	1.0	30
66	Sofosbuvir and Ribavirin Liver Pharmacokinetics in Patients Infected with Hepatitis C Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	29
67	Renal Transporter-Mediated Drug-Drug Interactions: Are They Clinically Relevant?. <i>Journal of Clinical Pharmacology</i> , 2016, 56, S73-81.	2.0	28
68	Chemoprophylaxis With Oral Emtricitabine and Tenofovir Alafenamide Combination Protects Macaques From Rectal Simian/Human Immunodeficiency Virus Infection. <i>Journal of Infectious Diseases</i> , 2016, 214, 1058-1062.	4.0	28
69	A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 82-92.	1.5	27
70	Synthesis and anti-HIV activity of 2- ² -fluorine modified nucleoside phosphonates: Analogs of GS-9148. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 1116-1119.	2.2	26
71	Interactions of enantiomers of 2- ² ,3- ² -didehydro-2- ² ,3- ² -dideoxy-fluorocytidine with wild type and M184V mutant HIV-1 reverse transcriptase. <i>Antiviral Research</i> , 2002, 56, 189-205.	4.1	24
72	Metabolic Activation of the Anti-Hepatitis C Virus Nucleotide Prodrug PSI-352938. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3767-3775.	3.2	24

#	ARTICLE	IF	CITATIONS
73	Probing the Mechanistic Consequences of 5-Fluorine Substitution on Cytidine Nucleotide Analogue Incorporation by HIV-1 Reverse Transcriptase. <i>Antiviral Chemistry and Chemotherapy</i> , 2003, 14, 115-125.	0.6	22
74	Beyond drug-drug interactions: effects of transporter inhibition on endobiotics, nutrients and toxins. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 1075-1087.	3.3	20
75	GS-9219/VDC-1101 - a prodrug of the acyclic nucleotide PMEG has antitumor activity inspontaneous canine multiple myeloma. <i>BMC Veterinary Research</i> , 2014, 10, 30.	1.9	19
76	Involvement of Drug Transporters in Organ Toxicity: The Fundamental Basis of Drug Discovery and Development. <i>Chemical Research in Toxicology</i> , 2016, 29, 545-563.	3.3	18
77	Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures. <i>Antiviral Research</i> , 2017, 140, 116-120.	4.1	18
78	Effect of Nucleoside and Nucleotide Reverse Transcriptase Inhibitors of HIV on Endogenous Nucleotide Pools. <i>Antiviral Therapy</i> , 2008, 13, 789-797.	1.0	17
79	Intracellular Nucleotide Levels during Coadministration of Tenofovir Disoproxil Fumarate and Didanosine in HIV-1-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1549-1555.	3.2	15
80	HCV NS5B polymerase inhibitors. <i>Current Opinion in Drug Discovery & Development</i> , 2010, 13, 441-65.	1.9	15
81	Investigating the effects of stereochemistry on incorporation and removal of 5-fluorocytidine analogs by mitochondrial DNA polymerase gamma: comparison of d- and l-D4FC-TP. <i>Antiviral Research</i> , 2004, 62, 57-64.	4.1	14
82	MECHANISTIC STUDIES TO UNDERSTAND THE INHIBITION OF WILD TYPE AND MUTANT HIV-1 REVERSE TRANSCRIPTASE BY CARBOVIR-TRIPHOSPHATE. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2001, 20, 1247-1250.	1.1	11
83	Preparation and biological evaluation of 1-cyano-2-C-methyl pyrimidine nucleosides as HCV NS5B polymerase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 3092-3095.	2.2	11
84	Species differences in liver accumulation and metabolism of nucleotide prodrug sofosbuvir. <i>Drug Metabolism and Pharmacokinetics</i> , 2020, 35, 334-340.	2.2	11
85	Effect of nucleoside and nucleotide reverse transcriptase inhibitors of HIV on endogenous nucleotide pools. <i>Antiviral Therapy</i> , 2008, 13, 789-97.	1.0	11
86	Targeting DNA Repair in Chronic Lymphocytic Leukemia Cells with a Novel Acyclic Nucleotide Analogue, GS-9219. <i>Clinical Cancer Research</i> , 2009, 15, 3760-3769.	7.0	10
87	Compared to Subcutaneous Tenofovir, Oral Tenofovir Disoproxil Fumarate Administration Preferentially Concentrates the Drug into Gut-Associated Lymphoid Cells in Simian Immunodeficiency Virus-Infected Macaques. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4980-4984.	3.2	10
88	Unlikely Association of Multidrug Resistance Protein 2 Single Nucleotide Polymorphisms with Tenofovir-Induced Renal Adverse Events. <i>Journal of Infectious Diseases</i> , 2007, 195, 1389-1390.	4.0	9
89	Evaluation of 2-fluorine modified nucleoside phosphonates as potential inhibitors of HCV polymerase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 3354-3357.	2.2	9
90	Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine. <i>Antiviral Therapy</i> , 2005, 10, 451-7.	1.0	9

#	ARTICLE	IF	CITATIONS
91	2,3-Didehydro-2,3-dideoxynucleosides are degraded to furfuryl alcohol under acidic conditions. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 2159-2162.	2.2	7
92	Bifunctional inhibition of HIV-1 reverse transcriptase: A first step in designing a bifunctional triphosphate. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 1511-1518.	2.2	7
93	Discovery of a 2-fluoro-2-C-methyl C-nucleotide HCV polymerase inhibitor and a phosphoramidate prodrug with favorable properties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1840-1847.	2.2	7
94	Role of Mitochondrial Toxicity in BMS-986094-Induced Toxicity. <i>Toxicological Sciences</i> , 2017, 155, 2-2.	3.1	7
95	Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations. <i>PLoS ONE</i> , 2017, 12, e0169948.	2.5	7
96	Synthesis of 1-C-Cyano Pyrimidine Nucleosides and Characterization as HCV Polymerase Inhibitors. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2015, 34, 763-785.	1.1	6
97	Nucleotide Prodrug Containing a Nonproteinogenic Amino Acid To Improve Oral Delivery of a Hepatitis C Virus Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	6
98	Mechanism of Anti-Human Immunodeficiency Virus Activity of 1-d-6-Cyclopropylamino-2,3-Didehydro-2,3-Dideoxyguanosine. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 1994-2001.	3.2	5
99	HCV RdRp, sofosbuvir and beyond. <i>The Enzymes</i> , 2021, 49, 63-82.	1.7	5
100	Interaction of 2-deoxyguanosine Triphosphate Analogue Inhibitors of HIV Reverse Transcriptase with Human Mitochondrial DNA Polymerase β . <i>Antiviral Chemistry and Chemotherapy</i> , 2007, 18, 25-33.	0.6	4
101	Synthesis and characterization of 1-C-cyano-2-fluoro-2-C-methyl pyrimidine nucleosides as HCV polymerase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 1040-1043.	2.2	3
102	Metabolism of Antiviral Nucleosides and Nucleotides. , 0, , 301-315.		1